Boehringer Ingelheim has announced the purchase of Swiss company T3 Pharmaceuticals AG for an amount that could reach up to 450 million Swiss francs (466 million euros).
T3 Pharmaceuticals, in clinical phase, has developed a unique therapeutic platform that uses live bacteria to deliver immunomodulatory proteins to cancer cells and tumor microenvironments.
The acquisition is part of Boehringer Ingelheim's objective to significantly increase long-term remission rates in cancer patients, leveraging complementary immuno-oncology platforms such as T-Cell Engagers (TcEs), oncolytic viruses, and cancer vaccines.
Michel Pairet, member of the Board of Directors of Boehringer Ingelheim, expressed that this acquisition will bring the company closer to its vision of changing the paradigm in cancer treatments.
T3 Pharma's innovative technology will strengthen Boehringer Ingelheim's portfolio of immunomodulatory cancer treatments, consolidating its oncology strategy to transform the lives of people affected by this disease.
T3 Pharma's bacterial delivery platform will be integrated with Boehringer Ingelheim's existing R&D programs, with the goal of fighting solid cancers.
Simon Ittig, CEO of T3 Pharma, expressed his pride in the team's work and excitement about accelerating the successful development of the platform in collaboration with Boehringer Ingelheim.
The pharmaceutical company adopts a comprehensive approach in the development of cancer therapies, exploring emerging science through a global network of academic and industrial partners, and investing in new companies through its Boehringer Ingelheim Venture Fund, which was one of the main investors in T3 Pharma.
With information from: Salud35.
Receive all industry news in our weekly Newsletter Scientific Dialectics.